Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Sunday, April 19, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location 7:00 AM - 4:45 PM GB Foyer 8:00 - 11:15 AM GB E Susan Butterworth, PhD Event Registration Desk and Evaluation Stations Open* Pre-Meeting Workshop: Motivational Interviewing ACPE #: 0284-0000-15-001-L04-P (Application) (3.0 hours) Learn and apply Motivational Interviewing (MI), an evidence-based and practical approach to patient communication that promotes resolution of ambivalence and behavior change. An extra fee is required to attend. 11:15 AM - 12:45 PM Promotional Product Theater and Lunch FL The Other Depression: Identifying and Treating Bipolar Disorder* Supported by Sunovion 1:00 - 4:30 PM GB A-D Resident Programming Track* 1:00-1:30 p.m. Leading Change Barbara Wells, PharmD, FCCP, FASHP Dr. Barbara Wells will get to the nitty-gritty of leadership by describing the challenges involved in leading change in pharmacy today. Focus will be placed on the role of the pharmacy leader in the evolving medical community and on practical leadership pearls for the emerging pharmacist. 1:30-2:00 p.m. CPNP and Leadership: What CPNP Can Do For You Jerry McKee, PharmD, MS, BCPP Envision how association involvement can make a difference in your future by learning what CPNP can provide you in terms of resources, connections, and leadership development. 2:00-3:00 p.m. Starting From Scratch: Creating a New Practice Beth DeJongh, PharmD, BCPS; Korin Richardson, PharmD, BCPP; Kelly Gable, PharmD, BCPP; Gain practical, first-person insight into the key components of creating a successful new practice. Learn methods to demonstrate the value of a new practice to promote growth and sustainability. 3:15-4:30 p.m. Ready, Set, BCPP Bill Ellis, Board of Pharmacy Specialties; Cynthia Kirkwood, PharmD, BCPP; Beth DeJongh, PharmD, BCPP; Amber Riesselman, PharmD, BCPP Representatives from the Board of Pharmacy Specialties (BPS) join us at CPNP 2015 to explain the criteria that must be met before qualifying to take the board certified psychiatric pharmacy (BCPP) examination. The content outline domains are described while recently successful BCPPs outline their preparation strategies. Recertification resources are described to allow soonto-be BCPPs to understand their options upon certification success. Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Sunday, April 19, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location 1:00 - 4:30 PM GB E Event Student Programming Track* 1:00-2:00 p.m. Substance Use Disorders and the Healthcare Professional Speaker Jake Nichols, PharmD, will discuss addiction and how it has impacted him personally. He will discuss the prevalence of substance abuse among healthcare providers and identify resources available for those struggling with addiction. 2:00-3:00 p.m. Pharmacy Practice Specialty Showcase Students will learn about career opportunities in neuropsychiatric pharmacy. The showcase will feature four practitioners presenting brief presentations on the specialty areas of substance use disorders, industry, academic detailing, and primary care. 3:15-4:30 p.m. Specialty Roundtable Discussions A variety of experts from differing practice areas will engage in small group discussions on what it is like to work in the specialty areas featured during the showcase. Students are encouraged to attend the Student Chapter Meeting (for existing chapters and interested individuals) from 6:30-7:00 p.m. in the Florida Ballroom and the Student networking event at Splitsville Lanes in the Channelside Bay Plaza from 7:30-9:30 p.m. (meal provided). 1:00 - 1:15 PM GB F-J 1:15 - 2:15 PM GB F-J George Brown, MD, DFAPA BCPP Recertification Opening Remarks* Pharmacotherapy Issues with Gender Dysphoria+ ACPE #: 0284-0000-15-002-L01-P (Application) (1.0 hours) Gender Dysphoria has received increasing attention as a treatable condition as part of the transgender health care equity movement in the United States. This session will address the epidemiology, diagnostics and barriers to care for individuals with gender dysphoria, as well as published standards of care to assist pharmacists in creating pharmacotherapeutic treatment plans for transgender individuals. Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Sunday, April 19, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location 2:15 - 3:15 PM GB F-J Riding the Roller Coaster: Exploring the Controversy Surrounding the Diagnosis and Treatment of Bipolar Disorder in Children and Adolescents+ ACPE #: 0284-0000-15-003-L01-P (Application) (1.0 hours) Sandra Mullen, PharmD, BCPP Overlapping symptomatology in child and adolescent psychiatry sometimes makes the diagnosis of bipolar disorder difficult to determine. This session will address the current controversies regarding the diagnosis of bipolar disorder in children and adolescents, differentiate the symptoms from other mental health disorders, and present the latest evidence for the use of pharmacotherapy regimens. 3:15 - 3:30 PM GB Foyer Refreshment Break* 3:30 - 4:30 PM GB F-J Kenneth Brasfield, PharmD, BCPP Medical Mimics: Differential Diagnosis of Psychotic Symptoms+ ACPE #: 0284-0000-15-004-L01-P (Application) (1.0 hours) When considering a psychiatric diagnosis, one should always be aware of the possibility of medical conditions contributing to or causing the clinical presentation. Methods for clinicians to distinguish between psychoses caused by medical conditions versus psychiatric disorders is to be addressed. Additionally, this session will outline how to assess patients for medical conditions that can contribute to psychotic symptoms and assist practitioners in creating both pharmacotherapy and monitoring plans to address psychosis associated with these conditions. 4:30 - 5:00 PM FL 5:00 - 6:30 PM FL 2015 Judith J. Saklad Memorial Award* Honoring Carla Cobb, PharmD, BCPP (Refreshments 4:30-4:40) CPNP Forum on Our Future* Participate in discussions with the CPNP Board on issues critical to the profession and CPNP as an organization. Based on your input, CPNP members will facilitate discussion on provider status and payment for services, expanding demand for psychiatric pharmacy services, and identifying the optimal neurology and psychiatry curriculum in pharmacy schools. These discussions will inform CPNP’s strategic discussions and directions. 6:30 - 7:30 PM Community Gatherings* Geriatric Care (GERI) Community (Mtg Room 5) Patient Care Practice Management (PCPM) Community (GB E) Patient Medication Education Groups (PMEG) Community (GB D) Research Community (Mtg Room 6) Residency Program Directors (RPD) Community (GB C) Residents (GB A-B) Substance Use Disorders Strategies (SUDS) Community (Mtg Room 1) Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Monday, April 20, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location Event 7:00 - 8:00 AM GB Foyer Breakfast* 7:00 AM - 4:30 PM GB Foyer Registration Desk and Evaluation Stations Open* 8:00 - 8:15 AM GB F-J Welcome from CPNP Leadership and Chair* 8:15 - 9:15 AM GB F-J The Science of Recovery in Severe Mental Illness ACPE #: 0284-0000-15-005-L04-P (Knowledge) (1.0 hours) Lisa Dixon, MD, MPH Dr. Lisa Dixon will present a keynote that considers the many dimensions and definitions of recovery and the importance of a new conceptualization of recovery involving illness and treatment understanding, empowerment through peers, family support, and illness management through helping others. 9:15 - 10:15 AM GB A-E Poster Session 1 and Break: Research Trainees* Manned by Authors 10:15 - 11:45 AM GB F-J Joseph Parks, MD Troy Trygstad, PharmD, MBA, PhD 11:45 AM - 1:45 PM FL ACA and Mental Health Care: Can We Deliver? ACPE #: 0284-0000-15-006-L04-P (Knowledge) (1.5 hours) The Affordable Care Act (ACA) made mental and behavioral health treatment 1 of 10 essential benefits required in new insurance policies and was expected to yield comprehensive coverage of mental illness. However, many of those seeking treatment are finding shortages of mental health providers and treatment facilities, as well as gaps in insurance coverage. With the advent of "whole patient" accountable care, a new set of economic incentives are transforming the larger health care system, and new collaborations are emerging, often with the desire to provide comprehensive medication management and coordination services. Drs. Joseph Parks and Troy Trygstad will discuss the impact of the ACA on mental health care and gaps in service delivery from the perspective of two different health care eco-systems and their innovative approaches to mental health care delivery. Symposium with Industry Support and Lunch The Pharmacists' Impact and Role: Understanding How to Better Diagnose and Treat Patients with Bipolar Type I Depression ACPE #: 0284-9999-15-060-L01-P (Knowledge) (1.5 hours) Supported by Sunovion Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Monday, April 20, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location 2:00 - 3:00 PM Concurrent Session GB F Event Track I: Issues of the Day The Impact of Sleep Disturbances on Depression and Suicide ACPE #: 0284-0000-15-007-L01-P (Knowledge) (1.0 hours) Michael Perlis, PhD Sleep disturbance and insomnia have long been considered to be symptoms of psychiatric illness. This point of view has shifted and it is now codified in several classification systems that insomnia is to be considered a disorder in its own right and that when it occurs concurrently with other disorders, is to be considered a comorbid. This session will provide a comprehensive overview regarding sleep and depression and sleep and suicide. 2:00 - 3:00 PM Concurrent Session Meeting Rooms 5-6 Track II: Research/Networking Award Finalist Platform Presentations ACPE #: 0284-0000-15-008-L04-P (Knowledge) (1.0 hours) Innovative Practices Award Finalists 2:00-2:15 p.m.: Melissa Brewster, PharmD, BCPS: Development and Implementation of a Pharmacist-Managed Intranasal Naloxone Distribution Program in a Veterans Affairs Healthcare Facility and Associated Community Clinics 2:15-2:30 p.m.: O. Greg Deardorff, PharmD, BCPP: Hematological Clozapine Monitoring With Finger Prick In A Forensic Inpatient Psychiatric Hospital Setting Therapeutic Case Report Award Finalists 2:30-2:45 p.m.: Nicole East, PharmD: Topiramate in the Treatment of Prader-Willi Syndrome 2:45-3:00 p.m.: Ian McGrane, PharmD, BCPS: Donepezil-Related Intractable Hiccups: A Case Report 2:00 - 3:00 PM Concurrent Session GB G-J Track III: BCPP Recertification Getting High on Knowledge: An Update on Substance Abuse+ ACPE #: 0284-0000-15-009-L04-P (Application) (1.0 hours) Michael O'Neil, PharmD Because of the strong relationship between mental illness and substance abuse, it is especially important for pharmacists practicing in mental health settings to stay abreast of substance abuse trends. Mike O’Neil, PharmD, will discuss the impact of the prescription and illicit substance abuse problem on healthcare systems, including pharmacists in the mental health setting, as well as obstacles providers in mental health settings may face when treating patients with substance use disorders. 3:00 - 3:15 PM GB Foyer Refreshment Break* Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Monday, April 20, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location 3:15 - 4:15 PM Concurrent Session GB F Event Track I: Issues of the Day Drug Metabolism: Beyond CYP450 ACPE #: 0284-0000-15-010-L01-P (Knowledge) (1.0 hours) John Markowitz, PharmD The CYP450 system is responsible for the metabolism of many psychotropic medications, and is also involved in a plethora of drug-drug interactions. There are, however, other enzyme systems responsible for drug metabolism. A good understanding of these enzyme systems are crucial in recognizing potential drug interactions. 3:15 - 4:30 PM Concurrent Session Meeting Rooms 5-6 Track II: Research/Networking Award Finalist Platform Presentations ACPE #: 0284-0000-15-011-L04-P (Knowledge) (1.25 hours) Original Research Award Finalists 3:15-3:30 p.m.: Kyle Burghardt, PharmD: The Pharmacoepigenetics of Metabolic Syndrome in Schizophrenia 3:30-3:45 p.m.: Ian McGrane, PharmD, BCPS: Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital Research Trainee Award Finalists 3:45-4:00 p.m.: Elizabeth Baltenberger, PharmD: Evaluation of Pharmacogenomic Testing of Patients with Treatment Resistant Depression and Schizophrenia within a VA Population 4:00-4:15 p.m.: Katherine Blissit, PharmD, BCPS: Safety of benzodiazepine use among four patient groups with Post-Traumatic Stress Disorder (PTSD) in a VA Medical Center 4:15-4:30 p.m.: Lindsey Peters, PharmD: Therapeutic Effects of Intranasal Insulin Aspart on Cognitive Function in Post-operative Delirium 3:15 - 4:15 PM Concurrent Session GB G-J Bethany DiPaula, PharmD, BCPP Track III: BCPP Recertification The Buprenorphine Debate: An Evidence-Based Look at Current Controversies+ ACPE #: 0284-0000-15-012-L01-P (Application) (1.0 hours) Buprenorphine is the only partial agonist therapy currently approved for managing opioid dependence in an office-based setting. Buprenorphine’s monitoring demands, unique medication properties, and risk for diversion allow for an important role for pharmacists. This session will discuss the evidence and controversies of buprenorphine/naloxone maintenance treatment with an emphasis on the psychiatric pharmacist’s role in managing these patients. 4:30 - 6:00 PM FL Promotional Product Theater Balancing Trade-offs in Schizophrenia (SCZ) Therapy: Understanding Compromises That May Make Some Patients and Caregivers Feel Frustrated* Supported by Otsuka America Pharmaceutical, Inc. 6:15 - 7:15 PM GB A-E Poster Session 2* Manned by Authors 7:15 - 8:15 PM GB Foyer Outgoing President's Reception Honoring Steven Burghart * Supported by TEVA Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Tuesday, April 21, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location Event 7:00 - 8:00 AM GB Foyer Breakfast* 7:00 AM - 4:45 PM GB Foyer Registration Desk and Evaluation Stations Open* 8:00 - 9:00 AM GB F-J Unraveling Torsades de Pointes; Implications for Clinical Practice ACPE #: 0284-0000-15-013-L01-P (Knowledge) (1.0 hours) Nancy Allen LaPointe, PharmD, MHS, AACC 9:00 - 9:15 AM GB Foyer 9:15 - 10:15 AM GB F-J Michael Friedman, PhD, MS 10:15 - 11:15 AM GB F-J Steven Chen, PharmD, FASHP, FCSHP, FNAP QT prolongation management continues to be a hot topic in psychiatric pharmacy practice, and it is imperative as the medication experts that we have a basic understanding of this concept and how the medications we use impact the QT interval. Dr. Allen LaPointe’s presentation will help psychiatric pharmacy specialists understand the relationship between QT interval prolongations and its implications/risk of occurrence of torsades de pointes (TdP). She will also review basic concepts in regard to QT prolongation and QT interval measurements. Finally, an overview of medications which increase risk of QT prolongation will be discussed and resources for use in QT prolongation will be presented. Refreshment Break* Stigma and Psychiatric Disorders: Understanding and Managing Personal Biases Jointly Provided by CPNP Foundation and CPNP ACPE #: 0284-9999-15-014-L04-P (Knowledge) (1.0 hours) Stigma surrounding psychiatric and substance use disorders can prevent individuals from seeking care and receiving potentially life-saving treatment. Dr. Friedman will discuss the prevalence of stigma amongst health care professionals, describe the impact on patient care, and offer strategies to help health care professionals recognize and manage their own personal biases. Collaborations to Improve Care: Psychiatric and Ambulatory Care Pharmacists ACPE #: 0284-0000-15-015-L04-P (Knowledge) (1.0 hours) Pharmacists are increasingly being used as providers in ambulatory care and clinic settings and can be tasked with treatment of psychiatric conditions. Collaboration between psychiatric and ambulatory care pharmacists can provide benefit to patients, providers, and clinics. Dr. Steven Chen will discuss deficits in providing mental health services, the resulting cost burden to primary care clinics, how to establish an effective practice model for integrating ambulatory care and psychiatric pharmacists into primary care clinics, and how to document the collaborative interactions. Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Tuesday, April 21, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location Event 11:15 AM - 12:45 PM Promotional Product Theater and Lunch FL Acute Treatment of Agitation Associated With Schizophrenia or Bipolar I Disorder* Supported by TEVA 1:00 - 2:00 PM Concurrent Session GB F-J Cindy O'Bryant, PharmD, BCOP, FCCP 1:00 - 2:00 PM Concurrent Session GB E Susan Fagan, PharmD, BCPS, FCCP 1:00 - 2:00 PM Concurrent Session GB A-D Track I: Ambulatory Care Approaches to Treating Depression in Patients with Cancer ACPE #: 0284-0000-15-016-L01-P (Knowledge) (1.0 hours) Up to a quarter of patients with cancer suffer from depression that may go unrecognized, affecting their quality of life. Confounding matters, many of the symptoms of depression can be often confused with side effects of cancer treatments. This session will review the literature related to depression in cancer patients and examine ways to distinguish depressive symptoms from disease or treatment related symptoms while identifying strategies for implementing appropriate therapy. Track II: Neurology Update on Stroke Management: A Primary Care Perspective ACPE #: 0284-0000-15-017-L01-P (Knowledge) (1.0 hours) This session will provide a summary of the most recently updated, evidence-based guidelines and recommendations on the prevention of secondary stroke, screening assessments, and new therapies for prevention. Decision points for control of risk factors and selection of therapies will be discussed. Track III: Research Pipeline Medications* The purpose of the Pipeline session is to present the very latest information about new CNS compounds to attendees at the CPNP Annual Meeting with the goal being that attendees will learn about the most promising agents in the specialty drug pipeline. 2:04-2:22 p.m.: Carolyn McMicken, PsyD: Idalopirdine: A Novel 5-HT6 Receptor Antagonist in Development for the Treatment of Alzheimer’s Disease 2:23-2:41 p.m.: Andrew Hsieh, PharmD: A Phase 2b, Randomized, Double-blind, Placebo-controlled, 12-week Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Partial Agonist, for Cognitive Impairment in Patients with Schizophrenia 2:42-3:00 p.m.: Candace Andersson, PhD: Development Update on Pimavanserin, a Novel 5HT-2A Receptor Inverse Agonist 2:00 - 2:15 PM GB Foyer Refreshment Break* Schedule and Session Descriptors * Not Approved for ACPE Contact Hours + Approved for BCPP Recertification Credit GB = Grand Ballroom FL = Florida Ballroom Tuesday, April 21, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location 2:15 - 3:15 PM Concurrent Session GB F-J Andy Mendenhall, MD 2:15 - 3:15 PM Concurrent Session GB E Event Track I: Ambulatory Care Pain Management of Co-Occurring Addiction and Chronic Pain ACPE #: 0284-0000-15-018-L01-P (Knowledge) (1.0 hours) Prescription opioid misuse and addiction among chronic pain patients are emerging public health concerns due to dramatic increases in deaths related to overdoses. The use of opioids in the chronic non-cancer pain patient population is controversial, even more so for patients with a history of addiction. Treatment strategies include maintenance buprenorphine use and interdisciplinary pain rehabilitation programs. Evidence suggests addiction and chronic pain are interrelated and effective treatment for both is necessary for successful outcomes. Track II: Neurology Traumatic Brain Injury: A Hard Hitting Problem ACPE #: 0284-0000-15-019-L01-P (Knowledge) (1.0 hours) Understanding the expanse of influence of TBI on psychiatric patient care continues Kimberly Arlinghaus, to be a challenge. Individuals with TBI have been known to experience a wide variety of MD symptoms including depression, mania, anxiety, headache, psychosis, aggression, apathy, poor attention, memory difficulties, and poor executive functioning. In this session, Dr. Arlinghaus will define traumatic brain injury, explain the scope of issues experienced in TBI, and discuss treatment options for cognitive and behavioral symptoms related to TBI. 3:30 - 4:30 PM GB F-J Clinical Pearls ACPE #: 0284-0000-15-020-L01-P (Knowledge) (1.0 hours) 4:32-4:46 PM: Brittany Finocchio, PharmD: Adjunctive Estrogen Therapy in Schizophrenia 4:46-5:00 PM: Shauna Garris, PharmD, BCPS: Use of Zolpidem for Catatonia 5:00-5:14 PM: Jonathan Lister, PharmD, BCPS: Treatment Options for ClozapineInduced Dyscrasias 5:14-5:28 PM: Korin Richardson, PharmD, BCPP: The Danger Zone: Where Benzodiazepines and Opiates Meet 4:45 - 5:45 PM Learning Labs* Clinical Pearls Deep Dive (GB F-J) Provider Status and Payment for Pharmacists' Services (Meeting Rooms 5-6) Veterans Affairs Pharmacists Discussion (GB E) 6:00 - 7:30 PM GB A-C Industry Supported Event Meet the Sunovion Medical Affairs Team* Supported by Sunovion Wednesday, April 22, 2015 (See cpnp.org/2015 for session information and downloads) Time/Location Event 7:00 - 8:00 AM (Meet at 6:50) Tampa Marriott Waterside Terrace NAMI Walk* 7:45 - 8:45 AM GB Foyer Breakfast* 8:00 AM - 12:00 PM GB Foyer Registration Desk and Evaluation Stations Open (evaluation stations close at 11:00 a.m.)* 8:20 - 8:30 AM GB F-J NAMI Walk Donation Presentation by the CPNP Foundation* 8:30 - 9:30 AM GB F-J Medications Used to Treat Mood Disorders in Pregnancy: Controversies and Clinical Dilemmas ACPE #: 0284-0000-15-021-L01-P (Knowledge) (1.0 hours) Marlene Freeman, MD Dr. Marlene Freeman will discuss current clinical controversies surrounding psychiatric medications used in the treatment of mood disorders during pregnancy. She will also discuss the risk versus benefit of using psychiatric medications in women of childbearing age and pregnancy. 9:30 - 10:00 AM GB Foyer Refreshment Break* 10:00 - 11:00 AM GB F-J Larry Ereshefsky, PharmD, BCPP, FCCP Brett English, PharmD, PhD 11:00 AM - 12:00 PM GB F-J Diana Perkins, MD, MPH New Approaches to Drug Development: Neurocircuitry Based Strategies Inspired by the Research Domain Criteria (RDoC) Initiative ACPE #: 0284-0000-15-022-L04-P (Knowledge) (1.0 hours) This presentation will focus on Early Drug Development describing novel approaches and technologies to enhance Phase I studies to inform & de-risk drug development to support Proof of Concept trials. An exciting new approach is the growing adoption of a Research Domain Criteria (NIMH initiative) influenced approach to drug development. The prioritization of behavioral, biomarker, and other neurophysiological measures that demonstrate engagement in neurocircuitry of relevance, can bring greater sensitivity to detect signal than typical behavioral measures (i.e., rating scales). The implications for drug development will be discussed in the context of a data driven presentation demonstrating these new technologies (quantitative EEG, Event Related Potential, fMRI, and cerebral spinal fluid sampling). Where Do We Stand with the Psychosis Risk Syndrome? ACPE #: 0284-0000-15-023-L01-P (Knowledge) (1.0 hours) This session will provide an overview of the psychosis risk syndrome, describe initiatives and emerging data on the risk for psychosis, and discuss potential treatment strategies to prevent conversion to psychosis.
© Copyright 2024